Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ATAvenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc. (ATXI)

Other OTC · Currency in USD
$0.39 ▼ -0.02 (-4.75%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.40
Open
$0.39
Day's Range
$0.39 – $0.39
52 Week Range
$0.15 – $0.97
Volume
200
Avg. Volume
5,462
Market Cap
$1.27M
Beta (5Y Monthly)
-0.17
PE Ratio (TTM)
--
EPS (TTM)
-$0.84
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: Avenue Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1
CEO
Alexandra MacLean

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$56.25
DateEst.Actual
Aug 6, 2026-$56.25-$0.21Beat
May 8, 2026-$56.25-$0.21Beat
Mar 30, 2026-$0.57-$0.22Beat
Nov 13, 2025-$0.94-$0.21Beat
Aug 14, 2025-$1.05$0.11Beat
May 15, 2025-$9.00-$0.62Beat

Analyst view

Consensus price target
$12.00 ▲ +3,016.9%
Range $12.00 – $12.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ATXI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.